Replies to post #12872 on NanoLogix Inc (NNLX)

[Omar8]

How is this related ?

Not sure why that below paragraph is mentioned last update and how it relates to Nanologix ?

Anyways, if one is interested here is a video with Daniel( I think was a board member years ago ?), and David, it at least lets you see and hear the new guy talk.

"The most recent book, co-authored with Michigan State University Professor of Law Daniel Barnhizer, is The Artificial Intelligence Contagion: Can Democracy Withstand the Imminent Transformation of Work, Wealth, and the Social Order? CONTAGION has been ranked as high as # 1 in Book Authority’s All-Time Top 100 books on Robotics and in the top ten in Book Authority’s All-Time list on artificial intelligence. "

[oilin07]

That's an update? Lol

[Omar8]

Didn't "believe " ??


"During the course of these events, and until their resolution, we did not believe we could approach investors for funding necessary for the further development of the technology. Nor could we seek development partners until this “Matter” was resolved. NanoLogix was delayed and blocked for approximately five months until the resolution of the “Matter” with no action recommended."


Don't they KNOW ? Seems like below they were seeking a partner. I found that "we did not believe", seems weird especially reading they entered into Confidentiality Agreements". Don't they have Lawyers who could tell them instead of " we did not believe" ? That was confusing.


"June 3, 2020

NanoLogix Seeks Development & Marketing Partner for Their Sub 1-Hour COVID-19 Detection Tests

HUBBARD, Ohio, June 3, 2020 /PRNewswire/ -- NanoLogix, Inc. (OTC: NNLX), an innovator in the rapid detection and identification of viruses and bacteria, is seeking a partner or partners for obtaining FDA Emergency Use Authorization, if required, and for development and marketing of their sub 1-hour COVID-19 Point of Care modified-ELISA detection test. This Rapid Viral Assay can also be configured for other viruses, such as, but not limited to, HIV, HPV, Hepatitis, MERS, and SARS-1. A Home-Test version of the COVID-19 test has the potential of 30-minute results using a nasopharyngeal swab or saliva samples.

CEO Bret Barnhizer stated: "NanoLogix does not possess the scale of production or marketing required for this essential test distribution for COVID-19. We cannot expand rapidly enough to meet the immediate need for testing. We have entered into Confidentiality Agreements with two diagnostic and financial groups in the last week for this purpose and are inviting additional interest."

[Omar8]

What if......


That company with an advanced diagnostic platform is the same one from that Dec 2015 release ?



Oct. 5, 2020

NanoLogix Covid-19 Detection Test Update – Partial Funding received from NanoLogix Directors Options Exercise

NanoLogix has enlisted the services of a company with an advanced diagnostic platform that can deliver lab-quality results at point-of-care (POC). That company will perform an initial feasibility assessment of our COVID-19 viral assay on their rapid POC system. Partial funding for the first phase of the feasibility assessment is being provided through NanoLogix Director and Chief Medical Officer Dr. Jonathan Faro and Director Dr. Sebastian Faro exercise of options for 3 million shares. Those exercised shares are restricted from trading for a period of one year from issuance




"NanoLogix Announces Diagnostic Customization for Major Medical Device Company

NNLX | December 21, 2015

HUBBARD, OH--(Marketwired - Dec 21, 2015) - NanoLogix, Inc. (OTC PINK: NNLX), an innovator in the rapid detection, identification and determination of the antibiotic resistance and sensitivity of bacteria, is very pleased to announce that they have been contracted by one of the world's three largest global Medical Device manufacturers to customize the NanoLogix N-Assay, a unique modified ELISA diagnostic.